STAB - Statera Biopharma updates on Nasdaq Listing Status

• Statera Biopharma ( NASDAQ: STAB ) provided an update on its request for a hearing before the Nasdaq Hearings Panel caused by delayed filing of its form 10-Q for the June quarter with the U.S. SEC in a timely manner.
• STAB had previously said that it had got non-compliance notices from Nasdaq regarding its inability to file its form 10-K for fiscal year 2021 and form 10-Q for the March quarter.
• The company timely requested a hearing and will request a further stay of any delisting action by Nasdaq pending the hearing, which is scheduled for October 6, 2022, and expiration of any extension that may be granted by the Panel.
• Last month, Statera Biopharma gets anticipated notice of additional filing delinquency from Nasdaq .
• Shares are up 6.44% after-hours .

For further details see: